Bilobalide

N/A

Report date: 2022/12/23 18:00:11

Base Information

Drug NameBilobalide
Drug Alias NameBilobalide (BB)Biloba leave extracts (denoted as EGb 761)
ClassificationSmall molecules > Heterocyclic drugsNatural product/Extract > Plants extract
Mechanisms of ActionApoptosis inhibitorsPeptide hydrolase inhibitors
TargetsPeptide hydrolase
Therapy Area/IndicationsDiabetes Mellitus, Type 2Central Nervous System DiseasesProtozoan Infections +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIndenaDr. Willmar Schwabe Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIndena
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Central Nervous System DiseasesProtozoan Infections +[4] 

Other Information

ATC CodeN/A
Related LinksN/A